文献速递糖尿病

高剂量与低剂量钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病中的临床不良事件:51项随机临床试验的Meta分析

Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本Meta分析纳入51项随机临床试验共24371例2型糖尿病患者,比较高剂量与低剂量SGLT2抑制剂的不良事件。总体安全性和特定安全性指标无显著差异,仅研究药物相关不良事件风险轻度增加(RR 1.08;95%CI 1.01-1.16),主要来自卡格列净(RR 1.17;95%CI 1.05-1.30)。结论认为SGLT2抑制剂的不良事件与剂量无关。

要点

  • 高剂量与低剂量SGLT2抑制剂的总体安全性和特定安全性无显著差异。
  • 研究药物相关不良事件风险轻度增加(RR 1.08;95%CI 1.01-1.16),主要来自卡格列净(RR 1.17;95%CI 1.05-1.30)。
  • SGLT2抑制剂的不良事件与剂量无关。

核心结论

  • SGLT2抑制剂的不良事件与剂量无关。

研究设计与样本

  • 检索MEDLINE、EMBASE和Cochrane Library从2006年1月1日至2020年3月10日,纳入报告高剂量与低剂量SGLT2抑制剂不良事件的随机临床试验。
  • 共纳入51项随机临床试验,涉及24371例患者(高剂量组12208例,低剂量组12163例)。
  • 采用随机效应模型计算汇总相对风险(RR)及95%CI,并进行预设亚组分析和留一法敏感性分析。

主要发现

  • 高剂量与低剂量SGLT2抑制剂在总体安全性(包括任何不良事件、严重不良事件、导致停药的不良事件和死亡)和特定安全性(包括感染和侵染、肌肉骨骼疾病、胃肠道疾病、渗透性利尿相关不良事件、容量相关不良事件、肾脏相关不良事件以及代谢和营养)方面无显著差异。
  • 研究药物相关不良事件风险轻度增加(RR 1.08;95%CI 1.01-1.16),主要来自卡格列净(RR 1.17;95%CI 1.05-1.30)。
  • 亚组分析结果与主要结局一致。

关键数值与推荐

  • 研究药物相关不良事件:高剂量组 vs 低剂量组 RR 1.08(95%CI 1.01-1.16)。
  • 卡格列净相关不良事件:高剂量组 vs 低剂量组 RR 1.17(95%CI 1.05-1.30)。
  • 纳入研究的异质性较低(每个结局的I² < 50%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The aims of this work are to assess the clinical adverse events (AEs) of high-dose vs low-dose sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) in patients with type 2 diabetes mellitus (T2DM). METHODS: We searched MEDLINE, EMBASE, and Cochrane Library from January 1, 2006 to March 10, 2020, for identifying eligible randomized clinical trials (RCTs) that reported AEs by high-dose and low-dose SGLT2 inhibitors in T2DM patients. Random-effects models was used to obtain summary relative risks (RRs) with associated 95% CIs. Prespecified subgroup analyses according to individual SGLT2 inhibitors and follow-up duration, and leave-one-out sensitivity analysis were conducted. RESULTS: A total of 51 RCTs involving 24 371 patients (12 208 received high-dose and 12 163 received low-dose SGLT2 inhibitors) were included. Overall, the heterogeneity among included studies was relatively low (I2 < 50% for each outcome). No significant differences between high-dose and low-dose SGLT2 inhibitors were observed for overall safety (including any AEs, serious AEs, AEs leading to discontinuation, and death) and specified safety (including infections and infestations, musculoskeletal disorders, gastrointestinal disorders, osmotic diuresis-related AEs, volume-related AEs, renal-related AEs, and metabolism and nutrition), except for a mild increase in risk for AEs related to study drugs (RR: 1.08; 95% CI, 1.01-1.16) that mainly derived from canagliflozin (RR: 1.17; 95% CI, 1.05-1.30). Subgroup analyses were consistent with the primary outcomes. CONCLUSIONS: This study provided substantial evidence that AEs of SGLT2 inhibitors were not dose related.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shi FH, Li H, Yue J, et al. Clinical Adverse Events of High-Dose vs Low-Dose Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of 51 Randomized Clinical Trials. J Clin Endocrinol Metab. 2020. PMID: 32841351. doi:10.1210/clinem/dgaa586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。